SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/049CB3649EAFC43176841FA2F76D0CBCE5087F7A58820BD1C5F1024234E41C52FFA9ACBBA6FB1B963F61208395ADD84B>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/049CB3649EAFC43176841FA2F76D0CBCE5087F7A58820BD1C5F1024234E41C52FFA9ACBBA6FB1B963F61208395ADD84B
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/049CB3649EAFC43176841FA2F76D0CBCE5087F7A58820BD1C5F1024234E41C52FFA9ACBBA6FB1B963F61208395ADD84B
http://www.w3.org/2000/01/rdf-schema#comment
"Results suggest that sequential ALK inhibitors can foster the emergence of compound ALK mutations conferring high level resistance to lorlatinib in ALK-positive lung neoplasm."
xsd:string
http://purl.uniprot.org/uniprot/#_D42AE73072404B379DF00FA2FF6B017DDA33AC8023883CF472283C3E3FFE82491FA44E26A1471877FF6997D0A8D69162
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/049CB3649EAFC43176841FA2F76D0CBCE5087F7A58820BD1C5F1024234E41C52FFA9ACBBA6FB1B963F61208395ADD84B
http://purl.uniprot.org/uniprot/B6D4Y6
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/049CB3649EAFC43176841FA2F76D0CBCE5087F7A58820BD1C5F1024234E41C52FFA9ACBBA6FB1B963F61208395ADD84B
http://purl.uniprot.org/uniprot/#_B6D4Y6-mappedCitation-29650534
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/049CB3649EAFC43176841FA2F76D0CBCE5087F7A58820BD1C5F1024234E41C52FFA9ACBBA6FB1B963F61208395ADD84B